

Financial Tear Sheet

Corporate Profile

We are a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. We have a comprehensive portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. Our orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. Our spinal fusion hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (“MIS”), complex spine, deformity and degenerative procedures. We believe our expertise in both orthobiologic sciences and spinal fusion hardware product development allows us to offer our surgeon customers a differentiated portfolio and a “complete solution” to meet their fusion requirements.

Stock Performance

SPNE (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$11.51
Change (%)	▲ 0.11 (0.96%)
Volume	39,558
52 Week Low	\$8.76
Market Cap	\$165,713,980
Rolling EPS	-4.26
PE Ratio	0
Shares Outstanding	14,536,314

Data as of 05/22/18 4:00 p.m. ET



Recent News & Upcoming Events

05/03/18

SeaSpine Reports First Quarter 2018
Financial Results

04/19/18

SeaSpine to Report First Quarter 2018
Financial Results on May 3, 2018

03/07/18

SeaSpine to Participate in the 38th Annual
Cowen Healthcare Conference

There are currently no events scheduled.

SEC Filings

Filing Date	Form
05/21/18	4
05/11/18	8-K
05/11/18	424B5
05/03/18	10-Q

Corporate Governance

Keith C. Valentine President, Chief Executive
Officer and Director

John J. Bostjancic Senior Vice President, Chief
Financial Officer

Tyler Lipschultz Senior Vice President,
Orthobiologics and
Business Development

Laetitia Cousin Vice President, Regulatory,
Clinical and Quality
Assurance

Patrick Keran General Counsel and
Corporate Secretary

Bill Rhoda General Manager of
Process Innovation and
Development

Chris Shen Vice President, Customer
Experience and Information
Technology

John J. Winge Vice President, Sales

Troy Woolley Vice President, Marketing

Data provided by Nasdaq. Minimum 15 minutes delayed.